on INVENTIVA (EPA:IVA)
Inventiva strengthens its leadership for phase 3 of lanifibranor
The biopharmaceutical company Inventiva announces the arrival of three new members to its management team. Axel-Sven Malkomes joins as Chief Financial Officer, Susan Coles as General Counsel, and Pamela Herbster as Chief Human Resources Officer.
These new hires come as Inventiva prepares to publish the results of its Phase 3 lanifibranor trial. Malkomes brings extensive experience in finance and acquisitions, having previously worked with BioNTech. Coles, with her expertise in life sciences law, previously worked for Vivet Therapeutics. Herbster, a human resources specialist, contributed to the success of Sage Therapeutics until its acquisition.
The company says it is ready to tackle this new stage with a strengthened team focused on key strategies and growth.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INVENTIVA news